The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

March 6 (Reuters) - Moderna Inc (MRNA.O), opens new tab said on Saturday it has agreed to supply the Philippines government 13 million doses of its COVID-19 vaccine, with deliveries set to begin in ...

A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...